Ovarian CarcinomaNCT01907789
Prophylactic Salpingectomy With Delayed Oophorectomy
A study testing Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy and Risk-Reducing Salpingo-Oophorectomy in people with Ovarian Carcinoma, run by M.D. Anderson Cancer Center at 2 sites in United States.
Trial summary
The goal of this clinical research study is to compare ovarian cancer screening, risk-reducing salpingo-oophorectomy (RRSO), and prophylactic salpingectomy with delayed oophorectomy (PSDO). The safety of RRSO and PSDO will also be studied. Ovarian cancer screening does not involve a surgical procedure. Read more about this study
- Who is it for?
- Ages 30 to 47 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Ovarian Carcinoma
- What is being tested?
- Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy and Risk-Reducing Salpingo-Oophorectomy
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesUnited States
- Study dates
- 26 Aug 2013to 31 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 47 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Premenopausal women with a documented BRCA1 or BRCA2 mutation. Menopause is defined as >/= 12 months of amenorrhea.
- Women must be at least 30 and less than 48 years of age.
- Candidate for surgery and willing to undergo two surgical procedures (if chooses the PSDO arm).
- Patient choosing PSDO or RRSO must desire permanent sterilization.
- Presence of at least one fallopian tube. Prior tubal ligation is allowed.
- Participants may have a personal history of non-ovarian malignancy, but must be without evidence of disease at enrollment and the patient must have completed treatment (including surgery, chemotherapy, or radiotherapy) > 3 months prior to enrollment (other than non-melanoma skin cancer). Current or past SERM or aromatase inhibitor use is allowed.
- Willingness to return to the enrolling site for any surgical procedures including pre-operative and post-operative care.
- Willingness to return to the enrolling site for ovarian cancer screening during the study period.
Who cannot join
- Postmenopausal women or women < 30 or >/= 48 years of age.
- Women without a documented BRCA mutation.
- Women with a history of ovarian, fallopian tube, or primary peritoneal cancer.
- Women currently undergoing cancer treatment or with a known active cancer. History of malignancy is allowed as long as the patient has completed treatment > 3 months prior to enrollment.
- Medical comorbidities making surgery unsafe as determined by the patient's surgeon.
- Prior bilateral salpingectomy. Prior unilateral salpingectomy is allowed.
Show all 11Show fewer
- Women who are pregnant. Patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta HCG, or best judgement of the investigator. Pregnancy testing is not required per protocol to determine study eligibility.
- Women desiring future fertility except in the screening arm of the trial.
- Women whose most recent CA125 or transvaginal ultrasound is abnormal. A history of abnormal CA125 or ultrasound is allowed, as long as the most recent testing is normal.
- Inability to provide informed consent.
- Inability to read or speak English.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
NorthShore University Health System
Evanston, Illinois, 60201
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
About this study
Official title: Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study
The goal of this clinical research study is to compare ovarian cancer screening, risk-reducing salpingo-oophorectomy (RRSO), and prophylactic salpingectomy with delayed oophorectomy (PSDO). The safety of RRSO and PSDO will also be studied.
Ovarian cancer screening does not involve a surgical procedure. Instead, physical exams, blood tests, and ultrasound are used to check for ovarian, fallopian tube, and peritoneal cancer.
Read more
The surgical procedures, RRSO and PSDO, are designed to lower your risk of ovarian cancer.
In RRSO, the fallopian tubes and ovaries are removed at the same time.
In PSDO, the fallopian tubes are removed and the ovaries remain in place so that the patient does not go through menopause. The ovaries are removed at a later date. The main goal of this study is to learn how many patients actually have their ovaries removed at a later date. Researchers also want to learn whether the removal of fallopian tubes will decrease the risk of ovarian cancer.
Read the detailed description
This study has 3 options: ovarian cancer screening, PSDO, and RRSO. You may choose which study group you want to take part in. However, you must let the researchers know what your choice is before any testing for the study begins. The 3 study groups are described in detail below.
GROUP 1: OVARIAN CANCER SCREENING:
Study Visits:
For this group, there is no testing required before starting the study. If you agree to be in Group 1, the following tests and procedures will be performed:
- You will have a physical exam, including a pelvic exam.
- You will have a transvaginal ultrasound (ultrasound inside the vagina) to look at your ovaries and fallopian tubes.
- Blood (about 2 tablespoons) will be drawn to measure your CA125 levels. This test is used to screen for ovarian cancer.
- You will complete a questionnaire about your quality of life. This should take up to 15 minutes.
Every 6 months for up to 3 years:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries and fallopian tubes.
At the end of Years 1, 2, and 3, you will complete the quality-of-life questionnaire.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a computed tomography (CT) scan or magnetic resonance imaging (MRI). If the results show cancer, the study doctor will refer you to a gynecologic oncologist (a doctor for women's cancer) and/or recommend that you have your ovaries and fallopian tubes removed.
Length of Study:
You may have study visits for up to 3 years. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
At any time or preferably at the end of 3 years, you will have the option to cross over and choose one of the treatment options (Group 2 or 3).
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history. If you are called, the calls should last about 5 minutes.
GROUP 2: FALLOPIAN TUBE REMOVAL WITH DELAYED OVARY REMOVAL (PSDO):
Salpingectomy:
If you are found to be eligible to take part in this study in Group 2, the study doctor will discuss the salpingectomy surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the salpingectomy will be scheduled.
Most patients have salpingectomy performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your fallopian tubes will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample or a complete ovary will be removed during surgery and tested. If cancer is found, a gynecologic oncologist would perform your cancer surgery.
Post-Salpingectomy Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing. The calls should last about 5 minutes.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions (wounds).
- You will complete the quality-of-life questionnaire.
The pathology (tissue) results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Ovarian Cancer Screening Period:
Every 6 months or until your delayed oophorectomy after the salpingectomy:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries.
You will complete the quality-of-life questionnaire 1 time a year until 1 year after your delayed oophorectomy.
Pre-Oophorectomy Testing:
After the 3-year screening period, you will have a pre-oophorectomy visit. The following tests and procedures will be performed:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for routine tests and CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries, if this has not been done in the last 6 months.
- You will complete the quality-of-life questionnaire, if this has not been done in the last 6 months.
- You may have other tests performed if the study doctor thinks it is needed.
Oophorectomy:
If your pre-surgical testing is normal, the study doctor will discuss the planned surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the oophorectomy will be scheduled.
Most patients have oophorectomy performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your ovaries will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample will be removed during surgery and tested.
Post-Oophorectomy Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions.
- You will complete the quality-of-life questionnaire.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
At 6 months and 1 year after surgery, you will complete the quality-of-life questionnaire.
At 1 year after surgery:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a CT scan or MRI. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Length of Study:
You will have study visits until 1 year after your oophorectomy. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history.
GROUP 3: REMOVAL OF FALLOPIAN TUBES AND OVARIES AT THE SAME TIME (RRSO):
RRSO:
If you are found to be eligible to take part in this study in Group 3, the study doctor will discuss the surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the RRSO will be scheduled.
Most patients have RRSO performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your ovaries and fallopian tubes will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample will be removed during surgery and tested.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Post-Surgery Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions.
- You will complete the quality-of-life questionnaire.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
At 6 months and 1 year after surgery, you will complete the quality-of-life questionnaire.
At 1 year after surgery:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn to measure your CA-125.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a CT scan or MRI. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Length of Study:
You will have study visits for up to 1 year after surgery. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history.
This is an investigational study. At this time, the only known method that may lower your risk of ovarian cancer is to have both of your ovaries and fallopian tubes removed (RRSO). Screening for ovarian cancer does not lower the risk that you will develop cancer. PSDO has not previously been studied and may not lower your ovarian cancer risk. PSDO is currently being used for research purposes only.
Up to 80 women will take part in this multicenter study. Up to 60 will be enrolled at MD Anderson.
- Conditions
- Ovarian Carcinoma
- Being tested
- Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, Questionnaire, Transvaginal Ultrasound
- Keywords
- Ovarian Carcinoma, Ovary, BRCA Mutation Carriers, BRCA1 or BRCA2 mutation, High risk for developing ovarian cancer, Ovarian cancer screening, Risk-reducing salpingo-oophorectomy, RRSO, Prophylactic salpingectomy with delayed oophorectomy, PSDO, Questionnaire, Quality of life, QOL, Survey, Transvaginal ultrasound, Phone call
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ovarian Cancer ScreeningOther
Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
Prophylactic Salpingectomy with Delayed OophorectomyProcedure or surgery
Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
Risk-Reducing Salpingo-OophorectomyProcedure or surgery
Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
QuestionnaireBehavioural
Also called Survey
Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery.
Transvaginal UltrasoundProcedure or surgery
Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline.
Phone CallBehavioural
Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly.
| Study group | Role | What they receive |
|---|---|---|
| Ovarian Cancer Screening | Experimental | Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound. Receives: Other: Ovarian Cancer Screening; Behavioral: Questionnaire; Procedure: Transvaginal Ultrasound; Behavioral: Phone Call |
| Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) | Experimental | Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure. Receives: Procedure: Prophylactic Salpingectomy with Delayed Oophorectomy; Behavioral: Questionnaire; Procedure: Transvaginal Ultrasound; Behavioral: Phone Call |
| Risk-Reducing Salpingo-Oophorectomy (RRSO) | Experimental | Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure. Receives: Procedure: Risk-Reducing Salpingo-Oophorectomy; Behavioral: Questionnaire; Procedure: Transvaginal Ultrasound; Behavioral: Phone Call |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Compliance with Prophylactic Salpingectomy with Delayed Oophorectomy Strategy
The proportion of women who comply with the prophylactic salpingectomy with delayed oophorectomy strategy estimated with an exact 95% binomial confidence interval. If all 20 patients return for their scheduled oophorectomy the 95% confidence interval for the proportion of women who are compliant will be 0.846 to 1.00.
Measured: Up to 5 years
Secondary outcomes (4)
Number of occult malignancies
Will be tabulated by study arm. The risk difference will be estimated for occult malignancies with 95% confidence intervals, where the risk is defined as the number of events divided by the total time at risk.
Measured: Up to 5 years
Number of complications
Will be tabulated by study arm. The risk difference will be estimated for complications with 95% confidence intervals, where the risk is defined as the number of events divided by the total time at risk.
Measured: Up to 5 years
Type of complications
Will be tabulated by study arm. The risk difference will be estimated for complications with 95% confidence intervals, where the risk is defined as the number of events divided by the total time at risk.
Measured: Up to 5 years
Change in quality of life measure
Descriptive statistics and box plots will be used to summarize the quality of life measures at each assessment time for each study arm.
Measured: Baseline to up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2013 (estimated)
- Study start26 Aug 2013
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CarcinomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Denise Nebgen, MD, PHD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01907789
- Sponsor's protocol ID
- 2013-0340
- Other IDs
- NCI-2015-00465
- Status last verified
- Oct 2026
- First submitted
- 18 Jul 2013
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study
- ClinicalTrials.gov ID
- NCT01907789
- Acronym / sponsor ID
- 2013-0340
- Conditions
- Ovarian Carcinoma
- Keywords
- Ovarian Carcinoma, Ovary, BRCA Mutation Carriers, BRCA1 or BRCA2 mutation, High risk for developing ovarian cancer, Ovarian cancer screening, Risk-reducing salpingo-oophorectomy, RRSO
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 26 Aug 2013 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 25 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical research study is to compare ovarian cancer screening, risk-reducing salpingo-oophorectomy (RRSO), and prophylactic salpingectomy with delayed oophorectomy (PSDO). The safety of RRSO and PSDO will also be studied.
Ovarian cancer screening does not involve a surgical procedure. Instead, physical exams, blood tests, and ultrasound are used to check for ovarian, fallopian tube, and peritoneal cancer.
The surgical procedures, RRSO and PSDO, are designed to lower your risk of ovarian cancer.
In RRSO, the fallopian tubes and ovaries are removed at the same time.
In PSDO, the fallopian tubes are removed and the ovaries remain in place so that the patient does not go through menopause. The ovaries are removed at a later date. The main goal of this study is to learn how many patients actually have their ovaries removed at a later date. Researchers also want to learn whether the removal of fallopian tubes will decrease the risk of ovarian cancer.
Detailed description
This study has 3 options: ovarian cancer screening, PSDO, and RRSO. You may choose which study group you want to take part in. However, you must let the researchers know what your choice is before any testing for the study begins. The 3 study groups are described in detail below.
GROUP 1: OVARIAN CANCER SCREENING:
Study Visits:
For this group, there is no testing required before starting the study. If you agree to be in Group 1, the following tests and procedures will be performed:
- You will have a physical exam, including a pelvic exam.
- You will have a transvaginal ultrasound (ultrasound inside the vagina) to look at your ovaries and fallopian tubes.
- Blood (about 2 tablespoons) will be drawn to measure your CA125 levels. This test is used to screen for ovarian cancer.
- You will complete a questionnaire about your quality of life. This should take up to 15 minutes.
Every 6 months for up to 3 years:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries and fallopian tubes.
At the end of Years 1, 2, and 3, you will complete the quality-of-life questionnaire.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a computed tomography (CT) scan or magnetic resonance imaging (MRI). If the results show cancer, the study doctor will refer you to a gynecologic oncologist (a doctor for women's cancer) and/or recommend that you have your ovaries and fallopian tubes removed.
Length of Study:
You may have study visits for up to 3 years. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
At any time or preferably at the end of 3 years, you will have the option to cross over and choose one of the treatment options (Group 2 or 3).
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history. If you are called, the calls should last about 5 minutes.
GROUP 2: FALLOPIAN TUBE REMOVAL WITH DELAYED OVARY REMOVAL (PSDO):
Salpingectomy:
If you are found to be eligible to take part in this study in Group 2, the study doctor will discuss the salpingectomy surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the salpingectomy will be scheduled.
Most patients have salpingectomy performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your fallopian tubes will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample or a complete ovary will be removed during surgery and tested. If cancer is found, a gynecologic oncologist would perform your cancer surgery.
Post-Salpingectomy Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing. The calls should last about 5 minutes.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions (wounds).
- You will complete the quality-of-life questionnaire.
The pathology (tissue) results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Ovarian Cancer Screening Period:
Every 6 months or until your delayed oophorectomy after the salpingectomy:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries.
You will complete the quality-of-life questionnaire 1 time a year until 1 year after your delayed oophorectomy.
Pre-Oophorectomy Testing:
After the 3-year screening period, you will have a pre-oophorectomy visit. The following tests and procedures will be performed:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for routine tests and CA-125 testing.
- You will have a transvaginal ultrasound to look at your ovaries, if this has not been done in the last 6 months.
- You will complete the quality-of-life questionnaire, if this has not been done in the last 6 months.
- You may have other tests performed if the study doctor thinks it is needed.
Oophorectomy:
If your pre-surgical testing is normal, the study doctor will discuss the planned surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the oophorectomy will be scheduled.
Most patients have oophorectomy performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your ovaries will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample will be removed during surgery and tested.
Post-Oophorectomy Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions.
- You will complete the quality-of-life questionnaire.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
At 6 months and 1 year after surgery, you will complete the quality-of-life questionnaire.
At 1 year after surgery:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn for CA-125 testing.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a CT scan or MRI. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Length of Study:
You will have study visits until 1 year after your oophorectomy. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history.
GROUP 3: REMOVAL OF FALLOPIAN TUBES AND OVARIES AT THE SAME TIME (RRSO):
RRSO:
If you are found to be eligible to take part in this study in Group 3, the study doctor will discuss the surgery with you in detail, including the risks and possible benefits. You will be asked to sign a surgical consent form. After that, the RRSO will be scheduled.
Most patients have RRSO performed as an outpatient procedure. This means that you will likely go home the day of your surgery. If the study doctor plans to have you stay overnight in the hospital for any reason, it will be discussed with you.
During the surgery, the inside of your abdomen will be looked at and both of your ovaries and fallopian tubes will be removed. If the study doctor finds anything during the surgery that may be cancerous, a tissue sample will be removed during surgery and tested.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Post-Surgery Follow-Up:
The study staff will call you 1 day and 1 week after surgery to ask how you are doing.
One (1) month after surgery:
- You will have a physical exam, including an exam of your surgical incisions.
- You will complete the quality-of-life questionnaire.
The pathology results from your surgery will be discussed with you at either the 1-week phone call or the 1-month visit. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
At 6 months and 1 year after surgery, you will complete the quality-of-life questionnaire.
At 1 year after surgery:
- You will have a physical exam, including a pelvic exam.
- Blood (about 2 tablespoons) will be drawn to measure your CA-125.
All of your test results will be discussed with you. If any of your test results are abnormal, the study doctor may ask you to have additional testing, which may include CA-125 testing, ultrasound, and/or a CT scan or MRI. If the results show cancer, the study doctor will refer you to a gynecologic oncologist.
Length of Study:
You will have study visits for up to 1 year after surgery. You will be taken off study early if you develop cancer or if you are unable to follow study directions.
Follow-Up:
One (1) time a year after your last study visit for as long as needed, the study staff will contact you by phone, e-mail, or letter to ask if you have had any changes in your medical history.
This is an investigational study. At this time, the only known method that may lower your risk of ovarian cancer is to have both of your ovaries and fallopian tubes removed (RRSO). Screening for ovarian cancer does not lower the risk that you will develop cancer. PSDO has not previously been studied and may not lower your ovarian cancer risk. PSDO is currently being used for research purposes only.
Up to 80 women will take part in this multicenter study. Up to 60 will be enrolled at MD Anderson.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Ovarian Cancer Screening | Experimental | Other: Ovarian Cancer Screening, Behavioral: Questionnaire, Procedure: Transvaginal Ultrasound, Behavioral: Phone CallWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound. |
| Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) | Experimental | Procedure: Prophylactic Salpingectomy with Delayed Oophorectomy, Behavioral: Questionnaire, Procedure: Transvaginal Ultrasound, Behavioral: Phone CallWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure. |
| Risk-Reducing Salpingo-Oophorectomy (RRSO) | Experimental | Procedure: Risk-Reducing Salpingo-Oophorectomy, Behavioral: Questionnaire, Procedure: Transvaginal Ultrasound, Behavioral: Phone CallWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure. |
Who may qualify
- Ages
- 30 to 47 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Premenopausal women with a documented BRCA1 or BRCA2 mutation. Menopause is defined as >/= 12 months of amenorrhea.
- Women must be at least 30 and less than 48 years of age.
- Candidate for surgery and willing to undergo two surgical procedures (if chooses the PSDO arm).
- Patient choosing PSDO or RRSO must desire permanent sterilization.
- Presence of at least one fallopian tube. Prior tubal ligation is allowed.
Key exclusion criteria (11 listed)
- Postmenopausal women or women < 30 or >/= 48 years of age.
- Women without a documented BRCA mutation.
- Women with a history of ovarian, fallopian tube, or primary peritoneal cancer.
- Women currently undergoing cancer treatment or with a known active cancer. History of malignancy is allowed as long as the patient has completed treatment > 3 months prior to enrollment.
- Medical comorbidities making surgery unsafe as determined by the patient's surgeon.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ovarian Cancer ScreeningWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound. | Other | Ovarian Cancer Screening |
| Prophylactic Salpingectomy with Delayed OophorectomyWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure. | Procedure or surgery | Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) |
| Risk-Reducing Salpingo-OophorectomyWoman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure. | Procedure or surgery | Risk-Reducing Salpingo-Oophorectomy (RRSO) |
| QuestionnaireAlso: SurveyOvarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3. Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy. Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery. | Behavioural | Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO), Risk-Reducing Salpingo-Oophorectomy (RRSO) |
| Transvaginal UltrasoundOvarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years. Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy. Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline. | Procedure or surgery | Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO), Risk-Reducing Salpingo-Oophorectomy (RRSO) |
| Phone CallOvarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up. Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly. | Behavioural | Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO), Risk-Reducing Salpingo-Oophorectomy (RRSO) |
Primary outcome
Patient Compliance with Prophylactic Salpingectomy with Delayed Oophorectomy Strategy
Time frame: Up to 5 years
The proportion of women who comply with the prophylactic salpingectomy with delayed oophorectomy strategy estimated with an exact 95% binomial confidence interval. If all 20 patients return for their scheduled oophorectomy the 95% confidence interval for the proportion of women who are compliant will be 0.846 to 1.00.
4 secondary outcomes
Number of occult malignancies
Time frame: Up to 5 years
Number of complications
Time frame: Up to 5 years
Type of complications
Time frame: Up to 5 years
Change in quality of life measure
Time frame: Baseline to up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- University of Texas MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Ovarian Carcinoma
Active, not recruiting
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
No Evidence of Disease, BRCA1 Syndrome
Active, not recruitingPhase 1
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Pancreatic Cancer, Renal Cell Cancer
Active, not recruitingPhase 2/3
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Denise Nebgen, MD, PHD principal investigator
M.D. Anderson Cancer Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy and Risk-Reducing Salpingo-Oophorectomy in people with Ovarian Carcinoma, run by M.D. Anderson Cancer Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Compliance with Prophylactic Salpingectomy with Delayed Oophorectomy Strategy (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.